Venous thromboembolism prevention in the acutely III medical patient: A review of the literature and focus on special patient populations

American Journal of Hematology

Volumn 79, Issue 3, 2005, Pages 229-237

  Pendleton, Robert ^a,c   Wheeler, Michelle ^b   Rodgers, George ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Control anticoagulants; Thromboembolism epidemiology; Thromboembolism prevention

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; HOSPITAL PATIENT; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; OBESITY; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

CRITICAL ILLNESS; HOSPITALIZATION; HUMANS; PULMONARY EMBOLISM; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 22044442538     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20360     Document Type: Short Survey

References (74)

1. Leizorovicz A, Cohen A, Turpie A, Olsson C, Vaitkus PT, Goldhaber SZ, PREVENT Investigator Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110(7):874-879.
2. Cohen A. Fondaparinux vs placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J Thromb Haemost 2003;1(Suppl 1 July):abstr P2046.
3. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341(11):793-800.
4. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(1 Suppl):132S-175S.
5. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost 2002; 28(Suppl 2):3-13.
6. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151(5):933-938.
7. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989;82(4):203-205.
8. Lethen H, Flachskampf FA, Schneider R, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol 1997; 80(8):1066-1069.
9. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991; 302(6778):709-711.
10. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997;50(7):609-610.
11. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. J Am Med Assoc 1986;256(6):744-749.
12. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. Br Med J 1992;305(6853):567-574.
13. Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74(6):1023-1028.
14. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160(22):3415-3420.
15. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152(8):1660-1664.
16. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. Stroke 2001;32(1):262-267.
17. Gallus AS, Nurmohammed M, Kearon C, Prins M. Thromboprophylaxis in non-surgical patients: who, when and how? Haemostasis 1998;28(Suppl 3):71-82.
18. Gallus AS. Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke. Haemostasis 2000; 30(Suppl 2):64-71; discussion 63.
19. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001;161(10):1268-1279.
20. Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest 2003;124(6 Suppl):357S-363S.
21. Davidson BL. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients. Haemostasis 2000;30(Suppl 2):77-81; discussion 63.
22. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. J Am Med Assoc 1995;274(4):335-337.
23. Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care. J Crit Care 2002;17(2):95-104.
24. Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Crit Care Med 1995;23(1):52-59.
25. Kearns PJ, Coleman S, Wehner JH. Complications of long-arm catheters: a randomized trial of central vs peripheral tip location. JPEN J Parenter Enteral Nutr 1996;20(1):20-24.
26. Allen AW, Megargell JL, Brown DB, et al. Venous thrombosis associated with the placement of peripherally inserted central catheters. J Vase Interv Radiol 2000;11(10):1309-1314.
27. Chemaly RF, de Parres JB, Rehm SJ, et al. Venous thrombosis associated with peripherally inserted central catheters: a retrospective analysis of the Cleveland Clinic experience. Clin Infect Dis 2002;34(9):1179-1183.
28. Trerotola SO, Kuhn-Fulton J, Johnson MS, Shah H, Ambrosius WT, Kneebone PH. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology 2000;217(1):89-93.
29. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. Chest 1998;114(1):207-213.
30. Otten HM, Prins MH, Smorenburg SM, Hutten BA. Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor. Haemostasis 2000;30(Suppl 2): 72-76; discussion 63.
31. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003;72(1):43-52.
32. Haddad FS, Kerry RM, McEwen JA, et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes. J Arthroplasty 2001; 16(1):37-46.
33. Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg 1992;164(3):265-268.
34. rd, Chang D, Velmahos G, et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg 2002;68(5):470-473.
35. Anglen JO, Goss K, Edwards J, Huckfeldt RE. Foot pump prophylaxis for deep venous thrombosis: the rate of effective usage in trauma patients. Am J Orthop 1998;27(8):580-582.
36. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10(7):448-450.
37. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988; 39(6):505-513.
38. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145(4):614-621.
39. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/ safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996;26(Suppl 2):49-56.
40. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83(1): 14-19.
41. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121(4):535-555.
42. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101(8):2955-2959.
43. de Lissovoy G, Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. Am J Manag Care 2002;8(12): 1082-1088.
44. Wade WE, Chisholm MA. Cost-effectiveness analysis of deep vein thrombosis prophylaxis in internal medicine patients. Thromb Res 1999;94(1):65-68.
45. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93(2):259-262.
46. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003:31(5):1405-1409.
47. Samama MM. Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery. Thromb Haemost 1995;73(6):977;AB300.
48. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12(1):19-24.
49. Casserly LF, Reddy SM, Dember LM. Venous thromboembolism in end-stage renal disease. Am J Kidney Dis 2000;36(2):405-411.
50. Wiesholzer M, Kitzwogerer M, Harm F, et al. Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis 1999;33(4): 702-708.
51. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105(3): 225-231.
52. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161(4 Pt 1):1109-1114.
53. Dorffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002;359(9309):849-850.
54. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002;359(9319): 1710-1711.
55. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140(11):867-873.
56. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999;5(4):259-266.
57. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8(2):114-117.
58. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003;1(7):1435-1442.
59. Massicotte MP. Low-molecular-weight heparin therapy in children. J Pediatr Hematol Oncol 2001;23(3):189-194.
60. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133(6):770-776.
61. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128(3):313-318.
62. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136(4):439-445.
63. Chan AK, Deveber G, Monagle P, Brooker LA, Massicotte PM. Venous thrombosis in children. J Thromb Haemost 2003;1(7): 1443-1455.
64. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251-1257.
65. Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr 1998;132(4):575-588.
66. Grandas OH, Klar M, Goldman MH, Filston HC. Deep venous thrombosis in the pediatric trauma population: an unusual event: report of three cases. Am Surg 2000;66(3):273-276.
67. Mahe I, Drouet L, Chassany O, Grenard AS, Caulin C, Bergmann JF. Low molecular weight heparin for the prevention of deep venous thrombosis: a suitable monitoring in elderly patients? Pathophysiol Haemost Thromb 2002;32(3):134-136.
68. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ. Making healthcare safer: a critical analysis of patient safety practices. AHRQ Publication No. 01-E058. Rockville, MD: Agency 6for Healthcare Research and Quality; 2001. http:// www.ahrq.gov/clinic/ptsafety/.
69. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991;115(8): 591-595.
70. Bratzler DW, Raskob GE, Murray CK, Bumpus LJ, Piatt DS. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med 1998;158(17):1909-1912.
71. Anderson FA Jr, Tapson VF, Decousus H, et al. IMPROVE, a multinational, observational cohort study of practices in prevention of venous thromboembolism in acutely ill medical patients: a comparison with clinical study patient populations. Blood 2003; 102(11):AB1146.
72. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosraer DW, Forcier A, Patwardhan NA. Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med 1994;154(6):669-677.
73. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med 2001;345(13):965-970.
74. Patterson R. A computerized reminder for prophylaxis of deep vein thrombosis in surgical patients. Proc AMIA Symp 1998: 573-576.